INSM INSMED Inc Insider Trading

CLO Michael Alexander Smith sold 6,149 shares of INSM at $108.47; stock now at $106.24, down 50.1% from 52-week high.

Michael Alexander Smith, Chief Legal Officer, sold 6,149 shares (reducing holdings from 47,762 to 41,613 shares) under a pre-arranged 10b5-1 trading plan adopted on 2025-11-07, making this a scheduled, non-discretionary transaction. The sale occurred at $108.47 per share for total value of $666,982.03, while the company's current stock price stands at $106.24 within a 52-week range of $64.84–$212.75. INSMED remains unprofitable with net income of -$163,563,000.00 on quarterly revenue of $305,964,000.00, despite annual revenue growth of 66.7%. The broader context shows the stock has declined 50.1% from its 52-week high and 26.5% over the prior 30 days.

INSM Chair/CEO Lewis William sold 25,564 shares for $2.7M via scheduled 10b5-1 plan; stock down -49.3% from 52-week high

Lewis William executed 3 separate sales totaling 25,564 shares for $2,718,223.75 on 2026-05-18 under a pre-arranged 10b5-1 trading plan adopted 2025-09-04, reducing his holdings by 8.6%. The company is unprofitable ($-163.6M net income in latest full fiscal year) despite strong revenue growth (+66.7% annually) and a substantial $23.4B market cap. The stock has declined -24.4% over 30 days and -33.0% over 90 days, trading -49.3% below its 52-week high of $212.75. Because this transaction is scheduled under a 10b5-1 plan rather than discretionary, the timing reflects pre-established parameters rather than current market judgment. Lewis William's prior 5 sales at INSM (all on 2026-05-04) were followed by declines ranging from -14.5% to -17.2% over both 30- and 90-day periods, consistent with his broader cross-ticker track record showing an average 90-day return of -20.1% after his 20 prior sales.

INSM CFO Bonstein Sara sold 8,272 shares at $116.18 ($961.0K) on 2026-05-13, retaining 71,486 shares post-trade.

Bonstein Sara, Chief Financial Officer of Insmed Inc, sold 8,272 shares at $116.18 for total proceeds of $961,040.96, retaining 71,486 shares post-transaction. The sale occurred against a backdrop of significant price weakness — INSM is currently -48.7% from its 52-week high of $212.75, with the stock down -25.6% over the prior 30 days and -26.6% over the prior 90 days. Her cross-ticker track record across 20 prior sells shows an average 90-day return of +40.0% after sales, reflecting a 90d well-timed rate of 30.00%, meaning her prior dispositions have generally been followed by stock appreciation rather than declines. At INSM specifically, 3 of her 5 prior sells were well-timed at the 90-day mark, with the January 2026 sells each followed by meaningful declines (-8.0%, -6.9%, and -5.5% at 90 days), while the July 2025 sells preceded substantial rallies of +60.9% and +61.9% at 90 days.

INSM COO Adsett Roger sold 5,837 shares at $116.18 ($678.1K) on 2026-05-13; all 5 prior INSM sells were well-timed at 90 days.

Roger Adsett, Chief Operating Officer of Insmed Inc, sold 5,837 shares at $116.18 for total proceeds of $678,142.66, retaining 100,973 shares post-transaction. His 5 prior sales at INSM each produced negative 90-day returns (-29.9%, -29.6%, -29.2%, -8.0%, and -6.9%), making all 5 well-timed at the 90-day mark. The current price of $109.14 already reflects a -25.6% decline over the 30 days and a -26.6% decline over the 90 days preceding today, and sits -48.7% from the 52-week high of $212.75. Against a fundamental backdrop of $306.0M in quarterly revenue, +66.7% annual revenue growth, and a net loss of $-163.6M, investors may note that the post-transaction price movement continues to align with the negative 90-day return pattern observed across all 5 of Adsett's prior INSM sales.

INSM CMO Flammer sold 18,333 shares for $2.1M (May 13-14) under pre-arranged 10b5-1 plan; stock down 48.7% from 52-week high.

Flammer Martina M.D., Chief Medical Officer of INSMED Inc, executed three separate sales totaling 18,333 shares for $2,128,891.98 on May 13–14, 2026 at prices ranging from $112.76 to $117.54 per share. This sale reduced her holdings by 22.0% (from 83,243 to 64,910 shares) and was executed under a pre-arranged 10b5-1 trading plan adopted on 2025-02-27, meaning the transactions were scheduled rather than discretionary. The current stock price of $109.14 reflects a 48.7% decline from the 52-week high of $212.75 and a 25.6% drop over the past 30 days. INSMED remains unprofitable (net income of $-163.6M in the latest reported period) despite strong revenue growth of 66.7% year-over-year, signaling operational challenges at a $23.7B market-cap company. The scheduled nature of the 10b5-1 plan removes any timing inference from this particular transaction; investors should focus on the company's deteriorating stock price relative to fundamentals rather than on the insider's individual sale decision.

Chair and CEO Lewis William sold 13,283 shares of INSM at $116.18 on 2026-05-13 ($1.5M); stock down -48.7% from 52-week high.

Lewis William sold 13,283 shares at $116.18 while INSM trades at $109.14, down -25.6% over 30 days and -26.6% over 90 days from the transaction date. His prior five trades at INSM (all on 2026-05-04) each showed negative 90-day returns ranging from -14.5% to -17.2%, consistent with a pattern of selling ahead of price declines. The company is unprofitable with net income of $-163.6M against revenue of $306.0M, though annual revenue growth stands at +66.7%, indicating operational strain despite market expansion. The sale reduces his holdings from 301.2K to 287.9K shares while the stock remains down -48.7% from its 52-week high of $212.75.

CMO Flammer executes exercise-and-sell: 12,949 shares acquired and nearly all shares sold same-day at steep markup, realizing ~$1.3M proceeds.

Dr. Martina Flammer, Chief Medical Officer of Insmed, exercised 12,949 shares and then immediately sold 12,949 shares on the same day—a pattern that completely offsets her equity gain and locks in liquidity. The sale price significantly exceeded her exercise price, translating to approximately $1.3 million in total disposition proceeds. This represents her sixth and seventh open-market sales at Insmed over the past three years, as her trading activity has been exclusively selling (zero open-market purchases). Notably, all five of her prior sales at this company showed the stock declining afterward—a pattern of uniformly well-timed exits that suggests Flammer has consistently exited before downturns. The stock currently trades well below its 52-week high and has declined materially over the past month and quarter, while the company remains unprofitable despite strong revenue growth. The exercise-and-sell structure combined with her consistent exit timing suggests a pattern of disciplined liquidity management rather than a vote of confidence in the company's near-term direction.

INSM Chair & CEO Lewis William exercises options and sells 10,699 shares in net-neutral transaction, extending a consistent sell pattern at this ticker.

Lewis William, Chair and CEO of Insmed, executed a classic exercise-and-sell transaction — acquiring shares through two option exercises and immediately disposing of the same number of shares on the open market, leaving his net holdings unchanged. This filing represents his sixth through eleventh open-market sales at INSMED in the three-year window, continuing a pattern of consistent selling at this company. What makes this worth watching is his prior track record: across all five of his previous open-market sales at INSMED with measurable outcomes, the stock declined afterward in both the near term and over a longer horizon — meaning every prior exit proved well-timed at both the 30-day and 90-day mark. He executed the current sales while Insmed's stock trades well below its 52-week high and has declined significantly over both the past month and the prior three months. On the fundamentals side, the company is not yet profitable, though it has posted strong revenue growth year-over-year, which creates a mixed backdrop. The persistent sell pattern from the company's top executive, combined with a historically accurate exit record, makes this filing more notable than a typical exercise-and-sell would otherwise suggest.